GRAFT-VS-HOST DISEASE

This study tests whether adding the drug belumosudil to standard care can better prevent graft-versus-host disease (GVHD) in adults with blood cancer who have had a stem cell transplant. About 46 participants will receive belumosudil alongside their usual GVHD prevention medicine…

This study tests a device that removes specific immune cells from donated stem cells before transplant. The goal is to lower the risk of graft-versus-host disease, a serious complication where donor cells attack the patient's body. The study includes up to 90 children and young a…

This study tests whether adding etanercept to the standard drug ruxolitinib works better for severe graft-versus-host disease (GVHD) that doesn't respond to steroids. GVHD is a life-threatening complication after a stem cell transplant where donor cells attack the patient's body.…

This early-phase study tests a new stem cell transplant method for people with aggressive or returning acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially processed donor cells to reduce the risk of graft-versus-host disease, with the goal…

This study tests a daily pill called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, whose condition hasn't improved with at least two prior treatments. The goal is to see if the drug can safely control the dis…

This study tests the drug ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGVHD) that did not improve with steroids. cGVHD is a complication after a stem cell transplant where the donor cells attack the patient's body. The main goal i…

This early-phase study tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in 41 blood cancer patients receiving a half-matched stem cell transplant. The goal is to reduce dangerous immune reactions while …

This study tests whether giving more doses of the drug abatacept after a stem cell transplant can better prevent graft-versus-host disease (GVHD), a serious condition where donor cells attack the patient's body. About 160 people receiving a partially matched donor transplant will…

This study tests a personalized approach to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. Instead of giving the prevention drug Letermovir for a fixed 100 days, doctors will use a blood test to check when the patient's own immune syst…

This study tests whether a home-based aerobic and resistance exercise program is feasible for adults with graft-versus-host disease (GVHD) who are starting high-dose steroids after a stem cell transplant. The goal is to see if exercise can help manage complications like high bloo…

This study looks at why some people who have had a stem cell transplant continue to feel extremely tired and have trouble thinking clearly. Researchers will use brain scans and spinal fluid tests to see if inflammation in the brain is the cause. The goal is to better understand t…

This study provides yearly follow-up care for people who received a donor stem cell transplant at least three years ago. Researchers monitor for late side effects, disease return, and overall health through exams, blood tests, and imaging. The goal is to improve long-term care an…

This study is developing a questionnaire specifically for children and teens (ages 5-17) who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The goal is to create a tool that accurately captures how bothersome their symptoms are, since current scales …

This study looks at how the collection of bacteria, fungi, and viruses in the vagina changes in women who receive a stem cell transplant. Researchers want to learn why some women develop a painful condition called vulvovaginal graft-versus-host disease (GVHD). About 40 women will…